Jun 2026 (Q2 FY26) — Jul 29, 2026
uniQure Q2 FY26 — Regulatory Clarity for AMT-130 and Strong Balance Sheet
Read the full calluniQure (QURE) earnings
- Mar 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
uniQure earnings: last reported Wed, 29 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 3.6 | +127.3% YoY | Quarterly, as filed | Quarter to Mar 2026 | Revenue from operations as filed. |
| Operating margin | -1283.5 | +1226.4 pts YoY | Operating profit / revenue | Quarter to Mar 2026 | For the quarter; a change is in percentage points. |
| Net profit | -53.5 | Quarterly, as filed | Quarter to Mar 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$22.2 +1.93% · +$0.42
Performance −61.7% 1Y
1Y: $58 on 17 Oct 2025 → $22.2. High $70.59 (29 Oct 2025), low $9.03 (3 Mar 2026).
- Previous close
- $21.78
- 52-week range
- $9.03 – $70.59
- One year
- −65.27%
Overview
- Symbol
- QURE
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
uniQure earnings calls (QURE)
Financials
What the filings say
Net profit, year on year: −23% (quarter to mar 2026 against mar 2025).
| Line item | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 11 | 2 | 5 | 2 | 5 | 4 | 6 | 4 |
| Expenses | 57 | 43 | 51 | 47 | 50 | 54 | 57 | 49 |
| Operating profit | -44 | -40 | -46 | -39 | -44 | -51 | -51 | -46 |
| Operating margin | −395.6% | −1759.0% | −877.8% | −2510.0% | −833.6% | −1379.0% | −918.1% | −1283.5% |
| Interest | 16 | 17 | 15 | 15 | 16 | 17 | 15 | 14 |
| Profit before tax | -55 | -44 | -72 | -43 | -37 | -72 | -41 | -53 |
| Tax rate | −1.7% | 0.1% | −1.2% | −1.1% | −1.1% | −12.0% | 9.6% | −0.9% |
| Net profit | -56 | -44 | -73 | -44 | -38 | -81 | -37 | -54 |
| EPS ($ per share) | -1.16 | -0.91 | — | -0.82 | -0.69 | -1.38 | — | -0.85 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 4 |
| Reserves | -536 | -660 | -785 | -455 | -582 | -890 | -1,130 | -1,329 |
| Total liabilities | 94 | 126 | 96 | 213 | 229 | 624 | 563 | 626 |
| Fixed assets | 29 | 29 | 32 | 44 | 51 | 47 | 20 | 14 |
| Total assets | 274 | 449 | 340 | 809 | 705 | 832 | 557 | 825 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -76 | -99 | -135 | 288 | -145 | -146 | -183 | -178 |
| Cash from investing | -4 | -7 | -9 | -67 | -183 | -206 | 163 | -322 |
| Cash from financing | 158 | 249 | 7 | 95 | 1 | 363 | -59 | 415 |
| Net cash flow | 75 | 143 | -133 | 312 | -328 | 13 | -84 | -79 |
| Capital expenditure | -2 | -6 | -7 | -17 | -18 | -7 | -3 | -0 |
| Free cash flow | -78 | -104 | -142 | 271 | -163 | -153 | -186 | -178 |
Insider filings
90 filings between Nov 4, 2025 and Jul 2, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$22.08M
57 sales by 12 insiders
67% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 12
- Award — granted as compensation
- 21
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Kapusta Matthew C | — | $12.86M | Jul 2, 2026 |
| Kaye Jack | — | $2.69M | Jun 30, 2026 |
| Abi-Saab Walid | — | $2.61M | Jun 30, 2026 |
| Gut Robert | — | $1.76M | Jun 11, 2026 |
| Balachandran Madhavan | — | $858.9K | Jun 17, 2026 |
| O'Keefe Kylie | — | $431.2K | Jun 11, 2026 |
| KLEMT CHRISTIAN | — | $381.8K | Mar 4, 2026 |
| Potts Jeannette | — | $261.2K | Jun 15, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jul 2, 2026 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 plan | 4,282 | $194.5K |
| Jul 2, 2026 | Kapusta Matthew C CEO, Managing Director | Option exercise 10b5-1 plan | 21,082 | $408.8K |
| Jul 2, 2026 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 plan | 7,600 | $348.8K |
| Jul 2, 2026 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 plan | 9,200 | $408.8K |
| Jun 30, 2026 | Kaye Jack Director | Sale 10b5-1 plan | 4,107 | $190.9K |
| Jun 30, 2026 | Kaye Jack Director | Option exercise 10b5-1 plan | 4,107 | $152.0K |
| Jun 30, 2026 | Kaye Jack Director | Option exercise 10b5-1 plan | 17,060 | $344.3K |
| Jun 30, 2026 | Abi-Saab Walid Chief Medical Officer | Sale 10b5-1 plan | 10,000 | $464.6K |
| Jun 30, 2026 | Abi-Saab Walid Chief Medical Officer | Option exercise 10b5-1 plan | 10,000 | $55.9K |
| Jun 30, 2026 | Abi-Saab Walid Chief Medical Officer | Sale 10b5-1 plan | 20,000 | $928.0K |
| Jun 30, 2026 | Kaye Jack Director | Sale 10b5-1 plan | 17,060 | $792.1K |
| Jun 26, 2026 | Abi-Saab Walid Chief Medical Officer | Sale | 1,434 | $67.2K |
| Jun 25, 2026 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 plan | 28,716 | $1.44M |
| Jun 25, 2026 | Kapusta Matthew C CEO, Managing Director | Option exercise 10b5-1 plan | 28,716 | $910.6K |
| Jun 24, 2026 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 plan | 6,696 | $334.8K |
| Jun 24, 2026 | Kapusta Matthew C CEO, Managing Director | Option exercise 10b5-1 plan | 4,128 | $130.9K |
| Jun 18, 2026 | Kapusta Matthew C CEO, Managing Director | Option exercise 10b5-1 plan | 4,656 | $147.6K |
| Jun 18, 2026 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 plan | 4,656 | $232.8K |
| Jun 18, 2026 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 plan | 37,015 | $1.85M |
| Jun 17, 2026 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 plan | 11,585 | $563.6K |
| Jun 17, 2026 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 plan | 33,334 | $1.50M |
| Jun 17, 2026 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 plan | 56,929 | $2.47M |
| Jun 17, 2026 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 plan | 6,023 | $263.2K |
| Jun 17, 2026 | Kapusta Matthew C CEO, Managing Director | Option exercise 10b5-1 plan | 62,581 | $1.21M |
| Jun 17, 2026 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 plan | 23,977 | $1.02M |
| Jun 17, 2026 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 plan | 32,581 | $1.47M |
| Jun 17, 2026 | Balachandran Madhavan Director | Sale 10b5-1 plan | 1,690 | $72.0K |
| Jun 17, 2026 | Balachandran Madhavan Director | Sale 10b5-1 plan | 4,700 | $205.2K |
| Jun 17, 2026 | Balachandran Madhavan Director | Sale 10b5-1 plan | 5,295 | $249.3K |
| Jun 17, 2026 | Balachandran Madhavan Director | Option exercise 10b5-1 plan | 6,390 | $123.9K |
| Jun 17, 2026 | Kaye Jack Director | Option exercise 10b5-1 plan | 5,295 | $167.9K |
| Jun 17, 2026 | Balachandran Madhavan Director | Option exercise 10b5-1 plan | 5,295 | $167.9K |
| Jun 17, 2026 | Kaye Jack Director | Sale 10b5-1 plan | 5,295 | $225.4K |
| Jun 15, 2026 | Balachandran Madhavan Director | Sale 10b5-1 plan | 10,000 | $278.5K |
| Jun 15, 2026 | Balachandran Madhavan Director | Option exercise 10b5-1 plan | 10,000 | $84.9K |
| Jun 15, 2026 | Potts Jeannette Chief Legal Officer | Sale | 5,237 | $144.9K |
| Jun 11, 2026 | O'Keefe Kylie Chief Customer & Strat Officer | Sale | 15,936 | $431.2K |
| Jun 11, 2026 | Springhorn Jeremy P. Director | Sale | 1,993 | $53.9K |
| Jun 11, 2026 | POST LEONARD E Director | Sale | 1,993 | $53.9K |
| Jun 11, 2026 | Meek David D. Director | Sale | 1,993 | $53.9K |
| Jun 11, 2026 | Kaye Jack Director | Sale | 1,993 | $53.9K |
| Jun 11, 2026 | Jacques Rachelle Suzanne Director | Sale | 1,993 | $53.9K |
| Jun 11, 2026 | Gut Robert Director | Sale 10b5-1 plan | 2,726 | $73.8K |
| Jun 11, 2026 | Balachandran Madhavan Director | Sale | 1,993 | $53.9K |
| Jun 10, 2026 | Gut Robert Director | Sale 10b5-1 plan | 3,127 | $81.4K |
| Jun 10, 2026 | Gut Robert Director | Sale 10b5-1 plan | 2,645 | $69.0K |
| Jun 10, 2026 | Gut Robert Director | Option exercise 10b5-1 plan | 2,645 | $42.4K |
| Jun 10, 2026 | Springhorn Jeremy P. Director | Award | 7,550 | $0 |
| Jun 10, 2026 | POST LEONARD E Director | Award | 7,550 | $0 |
| Jun 10, 2026 | Kaye Jack Director | Award | 7,550 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for uniQure N.V.
Free account. Everything above stays public.
Write why you follow uniQure N.V. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading